Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Total Current Liabilities (2016 - 2025)

Traws Pharma's Total Current Liabilities history spans 14 years, with the latest figure at $11.1 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $11.1 million for Q4 2025, down 3.36% from a year ago — trailing twelve months through Dec 2025 was $11.1 million (down 3.36% YoY), and the annual figure for FY2025 was $11.1 million, down 3.36%.
  • Total Current Liabilities for Q4 2025 was $11.1 million at Traws Pharma, up from $7.9 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $11.5 million in Q4 2024 to a low of $5.9 million in Q1 2022.
  • The 5-year median for Total Current Liabilities is $8.2 million (2022), against an average of $8.4 million.
  • The sharpest move saw Total Current Liabilities tumbled 38.98% in 2021, then skyrocketed 55.08% in 2023.
  • Year by year, Total Current Liabilities stood at $6.1 million in 2021, then surged by 31.58% to $8.0 million in 2022, then increased by 14.59% to $9.2 million in 2023, then grew by 25.09% to $11.5 million in 2024, then decreased by 3.36% to $11.1 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $11.1 million, $7.9 million, and $7.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.